Prognostic role of Ebstein-Barr virus latent membrane protein-1 and Interleukin-10 expression in patients with nasopharyngeal carcinoma

Cancer Investigation

Volumn 22, Issue 4, 2004, Pages 483-491

  Özyar, Enis ^a   Ayhan, Ayşe ^a   Korcum, Aylin F ^a   Atahan, I Lale ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Ebstein Barr virus; Interleukine 10; Latent membrane protein 1; Nasopharyngeal carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 10; LATENT MEMBRANE PROTEIN 1; PARAFFIN;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; APOPTOSIS; CARCINOMA; CHILD; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-10; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS; SURVIVAL ANALYSIS; VIRAL MATRIX PROTEINS;

EID: 8644246545     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200026386     Document Type: Article

References (35)

1. Lee, A.W.M.; Law, S.C.K.; Ng, S.H.; et al. Retrospective analysis of nasopharyngeal carcinoma treated during 1976-1985: late complications following megavoltage irradiation. Br. J. Radiol. 1992, 65, 918-928.
2. Altun, M.; Fandi, A.; Dupuis, O.; et al. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int. J. Radiat. Oncol. Biol. Phys. 1995, 32, 859-877.
3. Al-Sarraf, M.; LeBlanc, M.; Shanker Giri, P.G.; et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopaharyngeal cancer: phase III randomized intergroup study 0099. J. Clin. Oncol. 1998, 16, 1310-1317.
4. Perez, C.A.; Venkata, R.D.; Marcial-Vega, V.; et al. Carcinoma of the nasopharynx: factors affecting prognosis. Int. J. Radiat. Oncol. Biol. Phys. 1992, 23, 271-280.
5. Roychowdhury, D.F.; Tseng, A., Jr.; Fu, K.K.; et al. New prognostic factors in nasopharyngeal carcinoma: tumor angiogenesis and C-erbB2 expression. Cancer 1996, 77, 1419-1426.
6. Klein, G. The Relationship of the Virus to Nasopharyngeal Carcinoma. In The Epstein-Barr Virus; Epstein, M.A., Aching, E.G., Eds.; Springer: New York, 1979, 340-350.
7. Elliott, K. Epstein-Barr virus-increasing evidence of a link to carcinoma. N. Engl. J. Med. 1995, 333, 724-726.
8. Young, L.S.; Dawson, C.; Clark, D.; et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J. Gen. Virol. 1988, 69, 1051-1065.
9. Hu, L.F.; Zhen, Q.F.; Zhang, Y.W.; et al. Differences in the growth pattern and clinical course of EBV-LMP1 expressing and nonexpressing nasopharyngeal carcinoma. Eur. J. Cancer 1995, 31, 658-660.
10. Horikawa, T.; Yoshizaki, T.; Sheen, T.-S.; et al. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 2000, 89, 715-723.
11. Zlotnik, A.; Moore, K.W. Interleukine-10. Cytokine 1991, 3, 366-371.
12. Hus, D.H.; De Waal Malefyt, R.; Fiorentino, D.F.; et al. Expression of IL-10 activity by Ebstein Barr virus BCRF1. Science 1990, 250, 830-832.
13. Matsuda, M.; Salazar, F.; Petersson, M.; et al. IL-10 pre-treatment protects target cells from tumor and allo-specýfýc cytotoxic T cells and down regulates HLA-class I expression. J. Exp. Med. 1994, 180, 2371-2376.
14. Nakagomi, H.; Dolcetti, R.; Bejarano, T.; et al. The Ebstein Barr virus latent membrane protein-1 (LMP1) induces IL-10 in Burkitt-lymphoma lines. Int. J. Cancer 1994, 57, 240-244.
15. Yao, M.; Ohshima, K.; Suzumiya, J.; et al. IL-10 and cytotoxic T cell response in EBV associated nasopharyngeal carcinoma. Int. J. Cancer 1997, 72, 398-402.
16. Fujieda, S.; Lee, K.; Sunaga, H.; et al. Staining of IL-10 predicts clinical outcome in patients with nasopharyngeal carcinoma. Cancer 1999, 85, 1439-1445.
17. Ozyar, E.; Yildiz, F.; Akyol, F.H.; et al. Comparison of AJCC 1988 and 1997 classifications for nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1999, 44, 1079-1088.
18. Ozyar, E.; Yildiz, F.; Akyol, F.H.; et al. Adjuvant high-dose-rate brachytherapy after external beam radiotherapy in nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2002, 52, 101-108.
19. Fleming, I.D.; Cooper, J.S.; Henson, D.E.; et al. AJCC Cancer Staging Manual, 5th ed.; Lippincott-Raven: Philadelphia, 1997; 31-39.
20. Shanmugaratnam, K.; Sobin, H.L. The World Health Organization histological classification of tumours of the upper respiratory tract and ear. Cancer 1993, 71, 2689-2697.
21. Ayhan, A.; Yasui, W.; Yokozaki, H.; et al. Reduced expression of nm23 protein is associated with tumor stage and distant metastasis in human colorectal carcinomas. Virchows Arch., B Cell. Pathol. 1993, 63, 213-218.
22. Kaplan, E.; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958, 55, 457-481.
23. Cox, D.R. Regression models and life tables. J. R. Stat. Soc., B 1972, 34, 187-220.
24. Wang, D.; Liebowitz, D.; Kieff, E. An EBV membrane protein expressed in mortalized lymphocytes transforms established rodent cells. Cell 1985, 43, 831-840.
25. Devergne, O.; McFarland, E.C.; Mosialos, G.; et al. Role of the TRAF binding site and NF-kappa B activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J. Virol. 1998, 72, 7900-7908.
26. Henderson, S.; Rowe, M.; Gregory, C.; et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein-1 protects infected B cells from programmed cell death. Cell 1991, 65, 1107-1115.
27. Miller, W.E.; Earp, H.S.; Raab-Traub, N. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J. Virol. 1995, 69, 4390-4398.
28. Klein, G. Viral latency and transformation: the strategy of Ebstein Barr virus. Cell 1989, 58, 5-8.
29. Fahraeus, R.; Rymo, L.; Rhim, J.S.; et al. Morphological transformation of human keratinocytes expressing the LMP gene of Ebstein Barr viruses. Nature 1990, 345, 447-449.
30. Zheng, X.; Yuan, F.; Hu, L. Effect of B lymphocyte and NPC derived ABV-LMP1 gene expression on in vitro growth and differentiation of human epithelial cells. Int. J. Cancer 1994, 57, 747-753.
31. Pathmanathan, R.; Prasad, U.; Sadler, R.; et al. Clonal proliferation of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 1995, 333, 693-698.
32. Ohshima, K.; Suzumiya, J.; Tasiro, K.; et al. EBV infection and associated products in nodal non-Hodgkin's lymphoma of human immunodeficiency-virus negative Japanese. Am. J. Hematol. 1996, 52, 21-28.
33. Cortes, J.E.; Talpaz, M.; Cabanillas, F.; et al. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood 1985, 86, 4702-4704.
34. Fujieda, S.; Saito, H.; Hoshino, T. Responses to killer cells in head and neck cancer patients. Eur. Arch. Otorhinolaryngol. 1990, 247, 176-181.
35. Young, M.R.I.; Wright, M.A.; Lozano, Y.; et al. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of cancer. Int. J. Cancer 1996, 67, 333-338.